Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
Search
Partnering with Constantia Flexibles for augmented reality
Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Boehringer Ingelheim leader in hatchery vaccination
Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
Building blocks of our future
Our global investment projects are the building blocks for improved healthcare and sustainability
garbage game
Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Health Equity: No distance is too far
India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim
Boehringer Ingelheim increases donation for emergency flood relief to EUR 1 million
World Patient Safety Day 2021
As a sign of support for World Patient Safety Day, Boehringer Ingelheim lights up buildings in orange.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal